Compare · APEN vs ZBH
APEN vs ZBH
Side-by-side comparison of Apollo Endosurgery Inc. (APEN) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APEN and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $17.63B, about 87.7x APEN ($201.0M).
- ZBH has hit the wire 11 times in the past 4 weeks while APEN has been quiet.
- ZBH has more recent analyst coverage (25 ratings vs 6 for APEN).
- Company
- Apollo Endosurgery Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $9.99+0.71%
- $91.13-2.79%
- Market cap
- $201.0M
- $17.63B
- 1M return
- -
- +2.00%
- 1Y return
- -
- -1.64%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 6
- 25
Apollo Endosurgery Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest APEN
- SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)
- SEC Form 15-12G filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
Latest ZBH
- Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
- Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
- BMO Capital Markets initiated coverage on Zimmer Biomet with a new price target
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Kurdikar Devdatt
- SEC Form 4 filed by Director Hagemann Robert
- SEC Form 4 filed by Director Higgins Arthur J
- SEC Form 4 filed by Director Kolli Sreelakshmi
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Shapiro Louis